Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA
Journal for ImmunoTherapy of Cancer · 2023-06 · 11 (6) · e006284
DOI: 10.1136/jitc-2022-006284 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 22.06.2023. Verfasst von Nicholas P Semenkovich und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Metabolism, and Lipid Research, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Circulating Tumor DNA. Die Arbeit wurde bisher 108-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIGMS NIH HHS, NIDDK NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Liquid biopsies using cell-free circulating tumor DNA (ctDNA) are being used frequently in both research and clinical settings. ctDNA can be used to identify actionable mutations to personalize systemic therapy, detect post-treatment minimal residual disease (MRD), and predict responses to immunotherapy. ctDNA can also be isolated from a range of different biofluids, with the possibility of detecting locoregional MRD with increased sensitivity if sampling more proximally than blood plasma. However, ctDNA detection remains challenging in early-stage and post-treatment MRD settings where ctDNA levels are minuscule giving a high risk for false negative results, which is balanced with the risk of false positive results from clonal hematopoiesis. To address these challenges, researchers have developed ever-more elegant approaches to lower the limit of detection (LOD) of ctDNA assays toward the part-per-million range and boost assay sensitivity and specificity by reducing sources of low-level technical and biological noise, and by harnessing specific genomic and epigenomic features of ctDNA. In this review, we highlight a range of modern assays for ctDNA analysis, including advancements made to improve the signal-to-noise ratio. We further highlight the challenge of detecting ultra-rare tumor-associated variants, overcoming which will improve the sensitivity of post-treatment MRD detection and open a new frontier of personalized adjuvant treatment decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Metabolism, and Lipid Research, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
- Division of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
- Division of Biology and Biomedical Sciences, Washington University School of Medicine, St. Louis, Missouri, USA.
- Department of Thoracic Oncology, Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
- Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.
- Division of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, USA aadel@wustl.edu.
ORCID-Profile: Nicholas P Semenkovich, Aadel A Chaudhuri
Förderung
- NIGMS NIH HHS
- NIDDK NIH HHS
- NCI NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of General Medical Sciences
- Children's Discovery Institute
- Washington University Alvin J. Siteman Cancer Research Fund
- V Foundation for Cancer Research
Zitieren
APA
Semenkovich, N. P., Szymanski, J. J., Earland, N., Chauhan, P. S., Pellini, B., & Chaudhuri, A. A. (2023). Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA. Journal for ImmunoTherapy of Cancer, 11(6), e006284. https://doi.org/10.1136/jitc-2022-006284
Vancouver
Semenkovich NP, Szymanski JJ, Earland N, Chauhan PS, Pellini B, Chaudhuri AA. Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA. Journal for ImmunoTherapy of Cancer. 2023;11(6):e006284. doi:10.1136/jitc-2022-006284
BibTeX
@article{Semenkovich2023,
author = {Semenkovich, Nicholas P and Szymanski, Jeffrey J and Earland, Noah and Chauhan, Pradeep S and Pellini, Bruna and Chaudhuri, Aadel A},
title = {Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {6},
pages = {e006284},
doi = {10.1136/jitc-2022-006284}
}
EUVIMED